サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：婦人科医薬品の世界市場：治療法別・適応症別・流通チャネル別・地域別の競合・予測・機会 (2027年)
市場調査レポート
商品コード
1063911

婦人科医薬品の世界市場：治療法別・適応症別・流通チャネル別・地域別の競合・予測・機会 (2027年)

Global Gynecology Drugs Market, By Therapeutics, By Indication, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027
出版日: | 発行: TechSci Research | ページ情報: 英文 199 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

婦人科医薬品の世界市場：治療法別・適応症別・流通チャネル別・地域別の競合・予測・機会 (2027年)
出版日: 2022年07月01日
発行: TechSci Research
ページ情報: 英文 199 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の婦人科医薬品の市場規模は、2021年に141億3,956万米ドルに達した後、8.64%のCAGRで成長し、2027年までに213億9,567万米ドルに達すると予測されています。

市場の主な促進要因として、女性のライフスタイルの著しい変化や、各種の婦人科系のがんや疾患の有病率の増加、オンライン販売チャネルの導入、効果的な治療薬の開発に向けた多額の投資などが挙げられます。

販売チャネル別に見ると、小売薬局が2021年に48.39%のシェアを獲得して、世界市場をリードしています。

当レポートでは、世界の婦人科医薬品の市場について分析し、全体的な市場規模の動向見通しや市場シェア構造 (治療法別・適応種別・流通チャネル別)、地域別・主要国の詳細動向、主な市場促進・抑制要因、企業間の市場競争構造、主要企業のプロファイル、今後の市場成長の方向性などを調査しております。

目次

第1章 製品概要

第2章 分析方法

第3章 エグゼクティブサマリー

第4章 顧客側の見解

  • ブランド認知度
  • 購入意思決定に影響を与える要因
  • 製品の選好：治療法別

第5章 世界の婦人科医薬品市場に対するCOVID-19の影響

第6章 世界の婦人科医薬品市場：将来展望

  • 市場規模とその予測
    • 金額ベース
  • 市場シェアとその予測
    • 治療法別 (非ホルモン療法、ホルモン療法)
    • 適応症別 (避妊、婦人科感染症、女性不妊症、閉経後障害、多嚢胞性卵巣症候群、婦人科がん、子宮内膜症)
    • 流通チャネル別 (小売薬局、病院薬局、オンライン薬局)
    • 地域別 (北米、欧州、アジア太平洋、南米、中東・アフリカ)
    • 企業別 (2021年)
  • 製品市場マップ

第7章 北米の婦人科医薬品市場：将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 北米：国別分析
    • 米国市場
    • カナダ市場
    • メキシコ市場

第8章 欧州の婦人科医薬品市場：将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 欧州：国別分析
    • ドイツ市場
    • フランス市場
    • 英国市場
    • イタリア市場
    • スペイン市場

第9章 アジア太平洋の婦人科医薬品市場：将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • アジア太平洋：国別分析
    • 中国市場
    • 日本市場
    • インド市場
    • オーストラリア市場
    • 韓国市場

第10章 南米の婦人科医薬品市場：将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 南米：国別分析
    • ブラジル市場
    • アルゼンチン市場
    • コロンビア市場

第11章 中東・アフリカの婦人科医薬品市場：将来展望

  • 市場規模とその予測
  • 市場シェアとその予測
  • 中東・アフリカ：国別分析
    • 南アフリカ市場
    • サウジアラビア市場
    • アラブ首長国連邦 (UAE) 市場

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の傾向と動静

第14章 競合情勢

  • 企業プロファイル
    • Eli Lilly and Company Ltd.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • F. Hoffmann-La Roche Ltd.
    • Allergan Plc.
    • Bayer AG
    • Abbott Laboratories Ltd.
    • AbbVie Inc.
    • GlaxoSmithKline Plc
    • Novartis Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Johnson and Johnson Inc.
    • Sanofi SA

第15章 戦略提言

図表

List of Figures

  • Figure 1: Global Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 2: Global Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 3: Global Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 4: Global Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 5: Global Gynecology Drugs Market Share, By Region, By Value, 2017-2027F
  • Figure 6: Global Gynecology Drugs Market Share, By Company, By Value, 2021
  • Figure 7: Global Gynecology Drugs Market Map, By Therapeutics, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 8: Global Gynecology Drugs Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 9: Global Gynecology Drugs Market Map, By Distribution Channel, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 10: Global Gynecology Drugs Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
  • Figure 11: North America Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 12: North America Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 13: North America Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 14: North America Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 15: North America Gynecology Drugs Market Share, By Country, By Value, 2017-2027F
  • Figure 16: United States Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 17: United States Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 18: United States Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 19: United States Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 20: Canada Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 21: Fertility Rate in Canada, 2005, 2010, 2015, 2020
  • Figure 22: Canada Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 23: Canada Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 24: Canada Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 25: Mexico Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 26: Mexico Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 27: Mexico Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 28: Mexico Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 29: Europe Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 30: Europe Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 31: Europe Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 32: Europe Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 33: Europe Gynecology Drugs Market Share, By Country, By Value, 2017-2027F
  • Figure 34: Germany Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 35: Fertility Rate in Germany, 2005, 2010, 2015, 2020
  • Figure 36: Germany Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 37: Germany Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 38: Germany Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 39: France Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 40: France Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 41: France Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 42: France Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 43: United Kingdom Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 44: Prevalence of Menopause Symptoms Experienced by Women at Work in United Kingdom, 2021
  • Figure 45: United Kingdom Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 46: United Kingdom Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 47: United Kingdom Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 48: Italy Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 49: Fertility Rate in Italy, 2005, 2010, 2015, 2020
  • Figure 50: Italy Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 51: Italy Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 52: Italy Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 53: Spain Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 54: Spain Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 55: Spain Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 56: Spain Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 57: Asia Pacific Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 58: Asia Pacific Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 59: Asia Pacific Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 60: Asia Pacific Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 61: Asia Pacific Gynecology Drugs Market Share, By Country, By Value, 2017-2027F
  • Figure 62: China Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 63: China Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 64: China Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 65: China Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 66: Japan Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 67: Estimated Share of Women in Japan Using any Contraceptive Method, 2005, 2010, 2015, 2020
  • Figure 68: Japan Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 69: Japan Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 70: Japan Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 71: India Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 72: Polycystic Ovary Syndrome Issues Among Women Across India, By Age Group, 2020
  • Figure 73: India Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 74: India Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 75: India Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 76: Australia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 77: Australia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 78: Australia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 79: Australia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 80: South Korea Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 81: South Korea Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 82: South Korea Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 83: South Korea Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 84: South America Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 85: South America Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 86: South America Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 87: South America Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 88: South America Gynecology Drugs Market Share, By Country, By Value, 2017-2027F
  • Figure 89: Brazil Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 90: Fertility Rate in Brazil, 2005, 2010, 2015, 2020
  • Figure 91: Brazil Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 92: Brazil Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 93: Brazil Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 94: Argentina Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 95: Total Female Population of Argentina, by Age Group, 2020 (in Millions)
  • Figure 96: Argentina Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 97: Argentina Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 98: Argentina Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 99: Colombia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 100: Colombia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 101: Colombia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 102: Colombia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 103: Middle East & Africa Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 104: Middle East & Africa Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 105: Middle East & Africa Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 106: Middle East & Africa Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 107: Middle East & Africa Gynecology Drugs Market Share, By Country, By Value, 2017-2027F
  • Figure 108: South Africa Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 109: Fertility Rate in South Africa, 2005, 2010, 2015, 2020
  • Figure 110: South Africa Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 111: South Africa Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 112: South Africa Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 113: Saudi Arabia Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 114: Saudi Arabia Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 115: Saudi Arabia Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 116: Saudi Arabia Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F
  • Figure 117: UAE Gynecology Drugs Market Size, By Value (USD Million), 2017-2027F
  • Figure 118: Total Female Population of UAE, by Age Group, 2020 (in Millions)
  • Figure 119: UAE Gynecology Drugs Market Share, By Therapeutics, By Value, 2017-2027F
  • Figure 120: UAE Gynecology Drugs Market Share, By Indication, By Value, 2017-2027F
  • Figure 121: UAE Gynecology Drugs Market Share, By Distribution Channel, By Value, 2017-2027F

List of Tables

  • Table 1: Infertility Statistics of United States
  • Table 2: Ovary Cancer Cases in Mexico, 2020
  • Table 3: Ovary Cancer Cases in France, 2020
  • Table 4: Ovary Cancer Cases in Spain, 2020
  • Table 5: Ovary Cancer Cases in China, 2020
  • Table 6: Cancer Statistics of Australia, 2020
  • Table 7: Ovary Cancer Cases in South Korea, 2020
  • Table 8: Ovary Cancer Cases in Colombia, 2020
  • Table 9: Cervix Uteri Cancer Cases in Saudi Arabia, 2020
目次
Product Code: 7427

The global gynecology drugs market was valued at USD14139.56 million in 2021 and is expected to grow at a steady CAGR of 8.64% in the forecast period, 2023-2027, to reach USD21395.67 million by 2027. The market is driven by the increased incidences of gynecological diseases and the rise in the elderly female population. Also, the high-end investments by the public and private players in research and development activities to improve the effectiveness of drugs and eliminate the side effects are expected to create lucrative growth opportunities for the global gynecology drugs market in the forecast period.

The rise in the female old age population is expected to fuel the demand for gynecology drugs as they are more prone and are at higher risk of getting affected by gynecological disorders. According to the World Population Prospects in 2021, about 9.5% of females above the age group of 60 years are vulnerable to getting affected by gynecological disorders. The growing old-age population is expected to fuel the demand for the global gynecology drugs market in the forecast period.

The global gynecology drugs market is segmented into therapeutics, indication, distribution channel, regional distribution, and competitive landscape. Based on regional distribution, the North American region dominated the market in 2021 and held 35.09% of the overall market share. The presence of major market players and well-developed healthcare infrastructure are the primary drivers for the gynecology drugs market. Also, the increased prevalence of breast cancer, menopausal disorders, busy lifestyles, and high stress in women is accelerating the demand for gynecology drugs.

Major companies operating in the global gynecology market are: Amgen Inc., F. Hoffmann La Roche Ltd., Novartis AG, Bayer AG, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, AstraZeneca Plc, Lupin Limited, Johnson and Johnson, Sanofi SA, Ferring Pharmaceuticals, amongst others.

Years considered for this report:

  • Historical Years: 2017-2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023-2027

Objective of the Study:

  • To analyze the historical growth and the market size of the global gynecology drugs market from 2017 to 2021.
  • To estimate and forecast the market size of the global gynecology drugs market from 2023 to 2027 and growth rate until 2027.
  • To classify and forecast the global gynecology drugs market is divided into therapeutics, indication, distribution channel, regional distribution, and competitive landscape.
  • To identify drivers and challenges for the global gynecology drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the global gynecology drugs market.
  • To conduct pricing analysis for the global gynecology drugs market.
  • To identify and analyze the profile of leading players operating in global gynecology drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of leading gynecology drugs manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the gynecology drugs manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the gynecology drugs manufacturers, distribution channels and presence of all major players operating in the global gynecology drugs market all over the world.

TechSci Research calculated the global gynecology drugs market size using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Gynecology drugs manufacturers/ suppliers/ distributors
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums, and alliances related to gynecology drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for industry stakeholders such as gynecology drugs manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.

Report Scope:

In this report, global gynecology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Gynecology Drugs Market, By Therapeutics:

  • Non-Hormonal Therapy
  • Hormonal Therapy

Gynecology Drugs Market, By Indication:

  • Contraception
  • Gynecology Infections
  • Female Infertility
  • Postmenopausal disorders
  • Polycystic Ovary Syndrome
  • Osteoporosis
  • Gynecology Cancers
  • Endometriosis
  • Others (Urogenital Malformation, UTI & others)

Gynecology Drugs Market, By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Gynecology Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global gynecology drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Factors Affecting Purchase Decision
  • 4.3. Product Preference, By Therapeutics

5. Impact of COVID-19 on Global Gynecology Drugs Market

6. Global Gynecology Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics (Non-Hormonal Therapy vs Hormonal Therapy)
    • 6.2.2. By Indication (Contraception, Gynecology infections, Female infertility, Postmenopausal Disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others)
    • 6.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies Online Pharmacies)
    • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 6.2.5. By Company (2021)
  • 6.3. Product Market Map

7. North America Gynecology Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Gynecology Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Gynecology Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Gynecology Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Distribution Channel

8. Europe Gynecology Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Gynecology Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. France Gynecology Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. United Kingdom Gynecology Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Italy Gynecology Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Gynecology Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Distribution Channel

9. Asia Pacific Gynecology Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia Pacific: Country Analysis
    • 9.3.1. China Gynecology Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Japan Gynecology Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. India Gynecology Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. Australia Gynecology Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapeutics
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. South Korea Gynecology Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapeutics
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Distribution Channel

10. South America Gynecology Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics
    • 10.2.2. By Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gynecology Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Gynecology Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Gynecology Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Gynecology Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapeutics
    • 11.2.2. By Indication
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. Middle East and Africa: Country Analysis
    • 11.3.1. South Africa Gynecology Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapeutics
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Gynecology Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapeutics
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Gynecology Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapeutics
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends and Developments

14. Competitive Landscape

  • 14.1. Company profiles
    • 14.1.1. Eli Lilly and Company Ltd.
    • 14.1.2. Pfizer Inc.
    • 14.1.3. Merck & Co., Inc.
    • 14.1.4. Amgen Inc.
    • 14.1.5. AstraZeneca Plc
    • 14.1.6. F. Hoffmann-La Roche Ltd.
    • 14.1.7. Allergan Plc.
    • 14.1.8. Bayer AG
    • 14.1.9. Abbott Laboratories Ltd.
    • 14.1.10. AbbVie Inc.
    • 14.1.11. GlaxoSmithKline Plc
    • 14.1.12. Novartis Ltd.
    • 14.1.13. Lupin Pharmaceuticals, Inc.
    • 14.1.14. Johnson and Johnson Inc.
    • 14.1.15. Sanofi SA

15. Strategic Recommendations